INmune Bio Skyrockets 27.1%: What's Fueling This Biotech Volatility?

Summary
• INMB surges 27.1% to $3.0511
• Intraday range of $2.41–$3.0511 amid sector turbulence
• Turnover jumps 16% as options activity spikes

INmune Bio’s 27.1% intraday surge has ignited a firestorm in the biotech sector, defying the broader market’s cautious tone. With the stock trading near its 52-week high of $11.64 and a 16% surge in turnover, the move aligns with a sector-wide shift toward speculative biotech plays. Sanofi’s $1.15B Vicebio acquisition and FDA regulatory turbulence are amplifying volatility, creating a perfect storm for momentum traders.

Sector Turbulence and Regulatory Uncertainty Drive INMB Volatility
INMB’s 27.1% rally reflects a combination of sector-wide optimism and regulatory uncertainty. The biotech sector is in flux, with Sanofi’s $1.15B Vicebio acquisition and Replimune’s FDA rejection sparking debates over approval standards. While INMB lacks direct news, its low float and speculative positioning make it a proxy for broader market sentiment. The FDA’s recent actions—ranging from Sarepta’s Elevidys shipment pause to AstraZeneca’s rare disease drug failure—have created a risk-on environment for smaller biotechs with high leverage ratios.

Options Volatility and Gamma-Driven Plays in a Ranging Market
• 200-day MA: $6.47 (far below current price)
• RSI: 58.66 (neutral to bullish)
• MACD: -1.08 (bullish crossover near zero)
• Bollinger Bands: Current price at 3.05 vs. middle band 3.12

INMB’s technicals suggest a short-term bullish breakout after a long-term range. The stock is trading above its 30-day MA ($4.54) but far below key 200-day support ($6.47). High-gamma options like INMB20251219C2.5 and INMB20260320C3 offer leveraged exposure. Both contracts have strike prices near the 52-week low ($1.89), making them ideal for a continuation of the 27.1% rally. The 2.5-call has 91.91% implied volatility and a 3.34% leverage ratio, while the 3.00-call has 87.12% IV and 3.63% leverage.

INMB20251219C2.5:
• Strike: $2.50 | Exp: Dec 19 2025 | IV: 91.91% | Delta: 0.719 | Theta: -0.00228 | Gamma: 0.197 | Turnover: $18.3M
• Why: High gamma and moderate delta make this ideal for a continuation of the 27.1% move. A 5% upside scenario (to $3.20) would generate $0.70 profit per contract.

INMB20260320C3:
• Strike: $3.00 | Exp: Mar 20 2026 | IV: 87.12% | Delta: 0.636 | Theta: -0.00179 | Gamma: 0.183 | Turnover: $10.1M
• Why: Lower delta but higher liquidity, this contract offers a safer play on the 52-week low rebound. A 5% move to $3.20 would yield $0.20 per contract.

Aggressive bulls should consider INMB20251219C2.5 into a break above $3.12 (Bollinger middle band). Traders should watch for a rejection at $3.0511 (intraday high) to confirm momentum.

Backtest INmune Bio Stock Performance
The 27% intraday surge in INMB resulted in mixed short-to-medium-term performance. While the 3-day win rate was 47.03%, indicating a majority of days with positive returns in the initial period, the 10-day and 30-day win rates were slightly lower at 48.25% and 47.55%, respectively. This suggests that while INMB showed strong immediate response to the surge, its momentum weakened over longer time frames. The maximum return during the backtest period was 2.95%, achieved on day 57, which was the latest day in the 30-day win rate calculation, indicating that the best performance was not immediately following the surge but rather towards the end of the 30-day period.

Biotech Sector Volatility: Position for Gamma-Driven Rallies
INMB’s 27.1% surge underscores the sector’s appetite for leveraged plays amid regulatory uncertainty. The stock’s technical setup—a short-term bullish breakout against a long-term downtrend—suggests a continuation of the rally if it holds above $3.0511. Sector leader Amgen (AMGN) rose 0.18% but remains a laggard compared to speculative biotechs. Investors should monitor options turnover and key support/resistance levels (2.31–2.43 and 7.62–7.79) for directional clues. A break above $3.12 (Bollinger middle band) could validate the bullish thesis, while a close below $2.41 (intraday low) would signal a reversal. Aggressive positions should target the INMB20251219C2.5 for gamma-driven gains if $3.0511 holds.